These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 6613612)

  • 1. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
    Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
    Eklund K; Forsman A
    Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acutely psychotic patients receiving high-dose haloperidol therapy.
    Remington G; Pollock B; Voineskos G; Reed K; Coulter K
    J Clin Psychopharmacol; 1993 Feb; 13(1):41-5. PubMed ID: 8486816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of clinical usefulness of decaldol (haloperidol decanoate) produced by WZF Polfa in Warsaw in long-term treatment of schizophrenia].
    Morasiewicz J; Baranowski P; Borys J; Jańska-Skomorowska M; Kiejna A
    Psychiatr Pol; 1995; 29(3):405-20. PubMed ID: 7652093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.
    Stevens A; Stevens I; Mahal A; Gaertner HJ
    Pharmacopsychiatry; 1992 Nov; 25(6):273-7. PubMed ID: 1494594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
    Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
    Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
    Viala A; Aymard N; Leyris A; Caroli F
    Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bromperidol decanoate in the residual phase of schizophrenia].
    Smeraldi E; Cocconcelli C; Canova L; Faravelli C; Marchetti FP; Mariani G; Rapisarda V
    Minerva Psichiatr; 1996 Mar; 37(1):39-44. PubMed ID: 8926856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum prolactin as a correlate of clinical response to haloperidol.
    Van Putten T; Marder SR; Mintz J
    J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN; Korpi ER; Kirch DG
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
    Roncoroni D
    Psychiatr Prax; 1984 Mar; 11(2):56-8. PubMed ID: 6144121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
    Wistedt B
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.